BIOtech Japan 2018 was successfully completed on June 29th
and Mycenax attracted many participants in 3 days consecutive exhibition. Mycenax showed innovative and exclusive research and development technologies, such as the MBI Fast, MBI JUMP, etc. Moreover, the self-developed product (TuNEX®) and bio-similar drug (LusiNEX) were highly praised by professionals, visitors, and visiting manufacturers, demonstrating strong R&D capabilities and fruitful results.
Mycenax is committed to providing our customers with the highest quality and fast one-stop service. Through our self-developed and successful launched drug experience in Taiwan, we are able to solve the difficulties that customers may face in the drug development process and give advance strategy planning amendments. The using of exclusive professional technology to quickly shorten the product development process demonstrates the CDMO strength of Mycenax. We are also promoting the self-developed biological drug TuNEX® and LusiNEX, a biosimilar drug to seek overseas partners, marketing, and co-development. Excitingly, TuNEX® and LusiNEX caused interest and inquiries from many manufacturers during the event.
BIOtech Japan 2018 was co-held with INTERPHEX JAPAN, Japan's largest pharma manufacturing show, and in-PHARMA JAPAN, a pharma ingredients show. It is Asia's leading Bio, Pharma R&D Event (Exhibition, Partnering, Conference) specialized in Biotechnology, Drug Discovery, Pharmaceutical Development, Regenerative Medicine and Personalised Medicine.